Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Randomized, controlled trials and subsequent observational studies in routine clinical practice have shown that intravenous recombinant tissue plasminogen activator is safe and effective when used in selected patients within 3h of the onset of acute ischemic stroke. Results of the ECASS III (European Cooperative Acute Stroke Study III) trial have now confirmed the finding of a previous meta-analysis of data from individual patients from smaller trials, which showed that the time-window for benefit actually extends to 4.5h. However, the absolute benefit of treatment falls substantially with time after the onset of ischemic stroke and clinicians should, therefore, still aim to treat patients with intravenous recombinant tissue plasminogen activator within 90 min of stroke onset, if at all possible. Ongoing trials aim to determine whether eligibility for thrombolysis can be extended in other ways, such as to patients aged over 80 years, patients with severe stroke, or patients with lacunar stroke.

Original publication

DOI

10.1038/ncpcardio1447

Type

Journal article

Journal

Nat Clin Pract Cardiovasc Med

Publication Date

03/2009

Volume

6

Pages

164 - 165

Keywords

Brain Ischemia, Fibrinolytic Agents, Humans, Infusions, Intravenous, Plasminogen Activators, Randomized Controlled Trials as Topic, Stroke, Time Factors, Treatment Outcome